Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $82

Benzinga Newsdesk www.benzinga.com Positive 85.5%

Neg 0% Neu 0% Pos 85.5%

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $80 to $82.